RT Journal Article
T1 The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial.
A1 Triulzi, Tiziana
A1 Bianchini, Giampaolo
A1 Di Cosimo, Serena
A1 Pienkowski, Tadeusz
A1 Im, Young-Hyuck
A1 Bianchi, Giulia Valeria
A1 Galbardi, Barbara
A1 Dugo, Matteo
A1 De Cecco, Loris
A1 Tseng, Ling-Ming
A1 Liu, Mei-Ching
A1 Bermejo, Begoña
A1 Semiglazov, Vladimir
A1 Viale, Giulia
A1 de la Haba-Rodriguez, Juan
A1 Oh, Do-Youn
A1 Poirier, Brigitte
A1 Valagussa, Pinuccia
A1 Gianni, Luca
A1 Tagliabue, Elda
K1 HER2
K1 breast cancer
K1 gene expression profile
K1 pertuzumab
K1 predictive biomarker
K1 trastuzumab
AB As most erb-b2 receptor tyrosine kinase 2 (HER2)-positive breast cancer (BC) patients currently receive dual HER2-targeting added to neoadjuvant chemotherapy, improved methods for identifying individual response, and assisting postsurgical salvage therapy, are needed. Herein, we evaluated the 41-gene classifier trastuzumab advantage risk model (TRAR) as a predictive marker for patients enrolled in the NeoSphere trial. TRAR scores were computed from RNA of 350 pre- and 166 post-treatment tumor specimens. Overall, TRAR score was significantly associated with pathological complete response (pCR) rate independently of other predictive clinico-pathological variables. Separate analyses according to estrogen receptor (ER) status showed a significant association between TRAR score and pCR in ER-positive specimens but not in ER-negative counterparts. Among ER-positive BC patients not achieving a pCR, those with TRAR-low scores in surgical specimens showed a trend for lower distant event-free survival. In conclusion, in HER2-positive/ER-positive BC, TRAR is an independent predictor of pCR and represents a promising tool to select patients responsive to anti-HER2-based neoadjuvant therapy and to assist treatment escalation and de-escalation strategies in this setting.
YR 2021
FD 2021-12-17
LK http://hdl.handle.net/10668/22494
UL http://hdl.handle.net/10668/22494
LA en
DS RISalud
RD Apr 11, 2025